Recommendation of the President – vaccine Arexvy

On 16 May 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 63/2025 on the evaluation of the vaccine Arexvy for the indication: active immunization for the prevention of lower respiratory disease caused by respiratory syncytial virus (RSV) in adults aged 60 years and older

Publication in Public Information Bulletin (BIP) >>